Chronic systemic inflammation (CSI) has recently been identified as a major contributor to common diseases ranging from cancer to metabolic disorders and neurologic alterations. In the last decade, we and others have generated genetically engineered mouse models for inflammatory diseases, which enable studying the molecular mechanisms of CSI. Recently, organ cross-talk induced by CSI under homeostatic and pathological conditions has begun to be appreciated. In this review, we will revisit whole organism physiology in relation to CSI originating from epithelial tissues, such as the skin and gut. Furthermore, we will discuss the current knowledge regarding the mechanisms, the specific immune cells and molecules responsible for inducing the most common comorbidities, such as cardiovascular, metabolic, and neurological complications, as well as bone loss, in heterogeneous diseases like psoriasis, atopic dermatitis, and inflammatory bowel disease. As it would be impossible to discuss all comorbidities of these diseases as well as all epithelial tissues, we present an overview with a special emphasis on our recent findings linking skin inflammation to bone loss.
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Chronic systemic inflammation
Chronic systemic inflammation (CSI) is a common denominator for a large number of diseases originating from a variety of tissues. The epithelial barriers of the skin and gut that protect our body from insults are at constant risk of suffering from inflammation due to wounds; environmental cues, e.g., microbes; ultraviolet radiation; as well as genetic factors. Specifically, the microbiota has gained major attention in the last decade for the pathogenesis of the skin and gut. Inflammatory mediators such as cytokines and chemokines are often secreted into the circulation, reaching other organs leading to 'systemic' effects ( Fig. 1) . A similar systemic involvement occurs in cancer patients suffering from cancer-associated cachexia, which is considered to have a major inflammatory component (for review see [1] ). It is important to note that although the chronic inflammatory disease starts in the epithelial tissue, the epithelial cells are not the sole cause of these diseases. A bidirectional cross-talk between epithelial cells and the underlying stromal cells is a likely scenario to initiate these diseases (for review in the context of cancer see review [2] ).
In this review, we will highlight inflammatory diseases originating from epithelial tissues of the skin and gut, and discuss the mechanisms of pathogenesis, with a special emphasis on the microbiota, as well as their comorbidities.
Psoriasis
Psoriasis is a chronic recurrent disabling skin disease that affects approximately 2% of the population. Persistent plaques of inflamed and scaly skin characterize the prototypic form of psoriasis, called psoriasis vulgaris. Histologically, psoriasis is characterized by the infiltration of innate and adaptive immune cells in the dermis and the epidermis, together with hyperproliferative keratinocytes. Genetically, psoriasis is a very complex, heterogeneous disease with many genetic susceptibility loci described in the literature (for review see [3] ).
The initial trigger(s) leading to the development of psoriasis are largely unknown. However, the central role of the immune system in the progression of the disease is underlined by the potent role of the interleukin (IL)-17/IL-23 pathway. IL-17, an inflammatory cytokine, first described to be an exclusive T-helper 17 product, is demonstrated to be highly pathogenic in psoriasis. Several recent studies revealed IL-17 expression in different immune cell types in inflammatory conditions of the skin and other organs; such as cd T cells, neutrophils, mast cells, and group 3 innate lymphoid cells (ILC3) [4] [5] [6] [7] [8] [9] [10] . Blockade of IL-17 is currently approved for the treatment of moderate-severe psoriasis. Moreover, IL-23, important for the expansion of Th17 cells as well IL-17 expression from ILC3s, is elevated in psoriasis and its blockade is highly effective in patients [11] .
Atopic dermatitis
Atopic dermatitis (AD) is an inflammatory disease with itchy, red, swollen skin affecting 15-30% children and up to 10% of adults [12] . AD has been characterized by barrier defects as well as deregulated immunity. AD was also shown to be a hyper IgE disease, however, to date it is still not clear whether anti-IgE therapies would benefit AD patients [13, 14] .
Filagrin, a protein which constitutes part of the stratum corneum and prevents transepidermal water loss, is often lost or reduced in AD patients [15] . Reduced expression of several barrier-associated proteins, such as the tight-junction proteins claudin, and the stratum corneum proteins loricrin and involucrin are also reported in AD patients [16] [17] [18] .
It is increasingly evident that barrier and immune system defects play a concurrent role in the pathogenesis of AD. Thymic stromal lymphopoietin (TSLP) is a cytokine highly expressed in keratinocytes in AD patients [19] . TSLP has been recently assigned an essential role in the development of allergic skin diseases by linking the barrier function to the immunity of skin. Although many cytokines and immune cell types have been described to be active in AD, much attention is now devoted to Th2 cells producing the cytokines IL-4 and IL-13. Pathway analyses of psoriasis and AD have shown that the IL-17 pathway is central to psoriasis, while IL-4/IL-13 seem to have a dominant role in AD [20] . Current treatment strategies under investigation for AD include the blockade of the IL-4 receptor a-subunit to inhibit the downstream actions of IL-4 and IL-13 [21] . 
Inflammatory bowel disease
The intestine is another essential epithelial barrier that protects the organism from environmental insults. Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a chronic inflammatory disease with unknown origin that affects around 1 in 1000 people and for which there is no cure [22] . Signals from the environment in the form of ingested food, the intestinal microflora, as well as genetic factors play a role in the pathogenesis of IBD. Similar to AD in skin, epithelial barrier dysfunction and immune dysfunction are intertwined in IBD [23] . Furthermore, IBD patients exhibit increased intestinal permeability, however, it is not clear whether this is a cause or consequence of the disease. Using genetically engineered mouse models (GEMMs), different laboratories have shown that an interaction between the tight junctions of intraepithelial cells and the commensal bacteria is necessary for proper functioning of the intestinal barrier [24] . However, more studies are necessary to determine the role of individual molecules and bacterial species.
As observed in AD, TSLP has a fundamental role in both barrier function and activation of the immune system in IBD. TSLP is expressed under homeostatic conditions in the gut, but is further induced by microbes, chemokines, and cytokines [25] . TSLP has also been shown to modulate the differentiation of Th2, Th17, and T-reg cells [26] .
Inflammatory cytokines such as TNFa, IFNc, IL-12, IL-23, and IL-17 are highly expressed in patients with IBD as well as in mouse models of IBD [27] . The data on Th1/Th2 cytokines are controversial depending on the system used and the IBD disease studied. The differential roles of IL-23 and IL-17, previously thought to act in concert, are now starting to be recognized. In mouse models of IBD, discussed in more detail in section 2.3., two different laboratories simultaneously showed that IL-23 blockade is beneficial, while IL-17 blockade has adverse effects [28, 29] . Consistent with the mouse data, IL-17A blockade did not reach efficacy in a proof-of-concept study in Crohn's patients [30] . On the other hand, IL-23 blockade has shown promising results in Phase II clinical trials in these patients, and are currently evaluated in Phase III trials [11, 31] .
Another cell type that has received a lot of attention in the pathogenesis of IBD is the IL-10-producing T-regs to suppress inflammatory processes [32] [33] [34] . Nonfunctional T-regs might also contribute to the exacerbated inflammatory response observed in IBD.
Mesenchymal stromal cells, namely the 'stroma' has also gained recent consideration for their contribution to the immunity of the intestine. The mechanisms by which these cells such as fibroblasts, pericytes, endothelial cells, and smooth muscle cells, carry out immunogenic functions is not well understood. However, their communication with the intestinal epithelial cells as well as T and B cells, and the cells of the innate immune system has been extensively documented. The bacterial load may also be controlled by this very heterogeneous group of cells [35, 36] .
Modeling human inflammatory diseases in mice Psoriasis
GEMMs are key for in-depth investigations of molecular disease mechanisms in particular for understanding the cause and initiation of diseases [3] . Many models have been developed in mice for the study of psoriasis including keratinocyte-specific expression of the transcription factor Stat3 [37] or the cytokine IL-17A [38] . Psoriasis can also be modeled by administration of Imiquimod that activates TLR signaling and leads to massive immune cell infiltration and keratinocyte hyperproliferation through the IL-17/IL-23 pathway [39] . Alternatively, recombinant murine IL-23 injected into the dermis of mice leads to a psoriasis-like disease in an IL-17-and IL-22-dependent manner [40, 41] . Recently, Henry et al. [42] reported that IL-1 family cytokines, such as the IL-36 members, can function as key initiators of skin inflammation in keratinocytes, following activation by neutrophil-derived proteases, leading to psoriasis-like features in a 3D human skin model in vitro.
We have generated powerful GEMMs for inflammatory skin diseases, some modeling human conditions, such as psoriasis [43] . Overall, the absence of components of the AP-1 (Fos/Jun) transcription factor complex in the skin epidermis affects major inflammatory signaling pathways. Constitutive deletion of JunB and c-Jun causes a TNFa-dependent lethal cachexia [44] . However, inducible inactivation of the two Jun/AP-1 genes in adult mice leads to a psoriasis-like skin disease within 2 weeks [43] . Importantly, the epidermal proteome of the mutant mice is comparable to psoriasis patient samples. Our analyses also revealed that for disease development, the activation of S100A8/ A9-dependent C3 complement as well as a miR-21-dependent TIMP-3/TACE pathway leading to TNF-a shedding are causally involved [45, 46] . Furthermore, constitutive epidermal-specific deletion of JunB (JunB Dep ) leads to a progressive multi-organ disease
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The FEBS Journal 284 (2017) 505-516 ª 2016 Federation of European Biochemical Societies involving skin inflammation, the hematopoietic lineage, and the bone compartment [47, 48] . Our data point to chronic inflammation originating from the skin as the initiating trigger of the systemic disease through up-regulation of IL-6, G-CSF, IL-17A, and other cyto/chemokines. The mechanisms by which AP-1 factors control inflammation are complex and celland stage-dependent. In skin keratinocytes, where JunB is expressed independently of the differentiation status, we have demonstrated that JunB directly controls the transcription of G-CSF and IL-6 by binding to the respective promoters [47, 49] . Other than the direct transcriptional effects of JunB on these cytokines, many other inflammatory mediators are controlled by JunB likely through the interaction of AP-1 with other transcription factors such as NFkB and Stat-3 [46] (for more details, see review [50] ).
Atopic dermatitis
Atopic dermatitis has historically not been as extensively studied as psoriasis, largely due to the lack of reliable mouse models. As its incidence is constantly increasing, AD is finally starting to receive more attention.
A spontaneous mouse model, namely the NC mice develop AD at highly variable frequencies depending on the mouse facility [51] . There have been reports using house dust mite allergen and bacterial antigen to increase the prevalence of disease in these mice [51] . Other nongenetic approaches to recapitulate several hallmarks of AD are epicutaneous sensitization methods such as tape stripping with OVA, or administration of Derp8 (for review see [52] ).
GEMMs have also been developed to model AD by expression of different cytokines such as TSLP, IL-4, IL-31, IL-18, and caspase-1 in keratinocytes, as well as deletion of transcription factor RelB and cathepsin E (for review see [52] ). Preliminary results from our laboratory indicate a role of Fra-2/AP-1 in the development of AD-like disease in mice (S. Wurm, J. Guinea-Viniegra, A. Bozec, M. Riemann, F. Weih, E. F. Wagner, unpublished data). Many of these models have been shown to develop AD-like eczema in the skin of mice, and will be useful for future characterization of cell types, molecules, and pathways involved in this disease. These models are also necessary for testing novel pharmaceutical agents for the improvement of different disease hallmarks of AD.
Inflammatory bowel disease
Modeling IBD in mice has been accomplished by chemical induction as well as genetic manipulation or administration of specific bacterial species to germ-free mice. Some of the most commonly used models include dextran sodium sulfate (DSS) or oxalozoneinduced colitis, as well as genetic deletion of IL-10 or caspase-1. However, more models manipulating a wide range of cytokines, transcription factors, and inflammasome components are available (for review see [53] ). Colitis is also induced by microbial delivery into the gut [53] . The heterogeneity of models for studying IBD makes conclusions drawn from single models hard to generalize. Several models, including the newly developed xenotransplants with patient-derived sample (PDX) models-patient-derived tissue xenograftsshould be utilized to solve the complex pathogenesis of IBD.
The pathogenesis of the IL-17/IL-23 pathway is complex in IBD. As briefly discussed above, it was recently demonstrated that IL-17 protects the epithelial barrier, thus its blockade leads to barrier permeability, whereas blockade of IL-23 inhibits this pathology and increases gut barrier function [28, 29] . While the results showed that cd T cells were the main IL-17 producers, the study led by Daniel Cua's group also showed that this expression is independent of IL-23 [29] . The effects of IL-23 on IL-17 expression by ILCs have also recently been revealed [54] . Further studies employing GEMMs that lack ILCs will shed light on the functional participation of these cells in IBD.
Given the major differences between the immune system of mice and humans, new approaches have been developed by the laboratory of Richard Flavell. 'Humanized' mice expressing human versions of cytokines and their receptors, such as M-CSF, IL-3/ GM-CSF, SIRPa, TPO in a Rag2À/À, Il2rgÀ/À background, termed MISTRG mice have recently been established and constitute powerful next generation mouse models with a 'humanized' immune system [55] . Because these GEMMs allow better grafting and can preserve human innate immune cell function, MISTRG mice may prove as improved recipients for PDX approaches to test the relevance of any newly discovered molecule/pathways in these chronic inflammatory diseases.
Role of the microbiome and microbesensing pathways
Maintaining homeostasis with microorganisms at the body 0 s natural barriers is critical for health. Disturbance of either the host immunity or the microbial ecosystem can result in disease-provoking dysbiosis as shown for IBD [56] . While the gut microbiome has been intensively studied, much less is known about the skin microbiome [57] [58] [59] . Recently, several reports suggest that the balance between the host and the microbiome plays an important role in skin immunity [60] [61] [62] . Dysbiosis of skin-resident microbes has been associated with a variety of dermatological pathologies, such as AD and psoriasis [59] . However, it remains unclear how alterations in microbial communities and the intrinsic features of the host are interconnected and how this affects disease progression.
Antimicrobial peptides/proteins (AMPs) are molecules that are described to have microbial suppression or killing properties. The most common AMPs described in skin are a-and b-defensins, cathelicidin, and S100A8/A9 proteins, although many more exist [63] . AMPs provide antibacterial effects mostly by direct binding to the bacterial surface using their positively charged properties. This binding leads to membrane disruption and bacterial lysis. Other mechanisms by which AMPs kill microbes have also been described. AMPs have immune modulatory effects which are described elsewhere, and will not be discussed in detail in this review [64] .
Unlike AD where colonization and infection by pathogens, such as S. aureus, is frequent, psoriasis is rarely complicated by infections. A hypothesis to explain this difference between the inflammatory skin disorders is the differential expression of AMPs. Although psoriatic lesions have excessive production of AMPs, such as hBD2, hBD3, and S100A8/9, AD patients show decreased production of these AMPs [65] . AMPs are expressed in keratinocytes at the highest levels in skin, although immune cells such as neutrophils, dendritic cells, T cells, mast cells, and monocytes have also been reported to produce AMPs upon inflammatory stimuli [64] .
We have shown that S100A8/9 proteins are highly expressed in the DKO* GEMM for psoriasis, and genetic deletion of S100A9 ameliorated the disease phenotype [45] . Furthermore, Lipocalin-2 (Lcn-2), another AMP, is an iron-binding protein that has been linked to protection of mice from Gram-negative bacterial infections, such as E. coli by sequestering ironladen siderophore [66] . We are currently evaluating the role of Lcn-2 in skin immunity in inflammation-prone Jun/AP-1-dependent GEMMs.
Commensal bacteria, such as S. epidermidis, also produce AMPs to protect the skin against pathogenic bacteria. Recently, Richard Gallo's group has described that dermal adipocytes produce cathelicidin upon S. aureus infections, and provide another layer of protection [67] . The mechanisms by which different AMPs show efficacy against specific species of bacteria are not clear. Furthermore, the sensing of Candida albicans by nerve fibers in the dermis has been described [68] . Thus, the interaction between several cell types including epidermal keratinocytes, dermal adipocytes, and immune cells as well as nociceptive fibers, and the production of AMPs as well as the activation of cytokine networks are important in the intricate homeostatic balance of a healthy epithelial barrier.
In the intestine, a-defensins are the most abundant AMPs and paneth cells are the major AMP producers. Expression of many AMPs, such as cathelicidin, hepcidin, bactericidal/permeability increasing protein, is up-regulated during IBD [69] . Although probable, it is still not clear whether AMPs play a functional role in disease processes, such as dysfunctional gut barrier or in dysbiosis of the microbiota with the host. Some studies are pointing toward a possible therapeutic potential of cathelicidin in DSS-induced colitis in mice. More studies are needed to reveal the function and therapeutic potential of AMPs in chronic systemic inflammatory diseases.
Comorbidities of chronic inflammatory diseases
It is largely unknown how an inflammatory response is intercalated into normal physiological mechanisms to initiate the pathology of common human diseases, such as psoriasis or IBD. Today we have powerful tools, e.g., GEMMs, PDX, but also direct access to patient material, and even innovative drugs, to answer some fundamental questions, and how acute and systemic inflammation affects disease progression across organs alone or in combination with prior treatment regimens.
Networks built by cytokines, growth factors, and transcription factors regulate homeostatic conditions. However, when these networks are perturbed locally by genotoxic or environmental insults, the altered signal outputs can cause widespread alterations in distant organ physiology and can be accountable for the development of comorbidities. As highlighted above, mouse models of these diseases are essential for the investigation of comorbidities, as human studies are complicated by many factors such as timing (separation of comorbidity vs. separate disease), differential treatment protocols, and heterogeneity.
Several comorbidities including metabolic, cardiovascular, neurologic effects, as well as bone loss have been reported for inflammatory diseases originating from the epithelia. Here, we will review the most prevalent comorbidities of psoriasis, AD, and IBD. Although there has been an expansion of reports regarding comorbidities of inflammatory skin diseases in recent years, much less is known about the complications of IBD. Thus, it is an urgent need to devote more time and effort into the study of comorbidities of these diseases, which are largely unexplored.
Bone loss
Bone undergoes constant internal and external regulation. This complex tissue is made up of different cell types with an intricate relationship to ensure proper function and remodeling of bone. Osteoblasts, osteocytes, and osteoclasts are the main cells involved in bone remodeling. Osteoblasts, the bone building cells, are of mesenchymal origin and osteocytes are terminally differentiated osteoblasts embedded into the bone matrix, where they form a complex network called the osteocyte canaliculi. Osteoclasts are of hematopoietic origin, resorb bone, and release growth factors from the bone matrix [70] .
The role of osteoclasts in local inflammatory diseases such as rheumatoid arthritis (RA), or psoriatic arthritis (PsA) has been well documented. Cytokines such as IL-6, TNFa, and IL-17 are produced by immune cells at the site of inflammation, activate NFjB, and in turn lead to RANKL production by synovial fibroblasts and osteoblasts, which is essential for osteoclast differentiation and function [71] . However, we recently described that inflammation originating distant from the bone leads to bone loss by a completely distinct mechanism. Using psoriasis patient samples and GEMMs for skin inflammation, we show that chronic skin inflammation leads to bone loss through inhibition of bone formation by IL-17A. Psoriasis patients with no arthritic involvement also show bone loss with decreased bone formation markers that correlates with circulating IL-17A levels [48] .
Deletion of JunB/AP-1 in Keratin-5-expressing tissues (JunB Dep ), e.g., skin epidermis, leads to massive skin inflammation with multi-organ involvement [47] . IL-17A is expressed by cd T cells and ILC3s in the skin of these mice. Molecular and structural analysis of bones revealed a decrease in bone formation, without any changes in bone degradation. A second mouse model of chronic skin inflammation, achieved by expression of IL-17A in Keratin-14-expressing epithelial tissues, displays similar bone phenotypes with decreased bone formation. Investigating the mechanism of inhibition of osteoblast function by IL-17A led to the identification of decreased Wnt pathway activity. Proper function of the Wnt pathway is essential for bone homeostasis, and mutations in Wnt pathway components lead to bone diseases (for review see [72] ). Blockade of a natural, potent inhibitor of the Wnt pathway, sclerostin, is currently under clinical investigation for the treatment of osteoporosis [73] . We observed decreased Wnt target gene expression both in osteoblast and osteocyte cultures in vitro and in bones from GEMMs in vivo. Importantly, IL-17A inhibition by administration of blocking antibodies to the JunB Dep mice led to the recovery of bone formation rates as well as Wnt target gene expression. However, sclerostin levels were not altered in the bones of GEMMs with chronic skin inflammation. Interestingly, another recent study described a so far unknown role for sclerostin in inflammatory bone loss [74] . Wehmeyer and colleagues demonstrate that sclerostin has a protective role in TNFa-dependent bone loss. These two reports showing unexpected findings in inflammatory bone loss emphasize the complexity of this organ and indicate the need for more studies for a better molecular understanding of this comorbidity. Surprisingly, neither psoriasis patient samples, nor GEMMs with chronic skin inflammation had increased RANKL levels. This is an interesting finding suggesting that a local inflammatory milieu is necessary for RANKL production by fibroblasts and osteoblasts. It is possible that another factor is expressed during CSI to suppress RANKL activation. It will be of future interest to determine if these mechanisms also hold true for AD.
Despite the clear clinical correlation between IBD and bone loss, the mechanisms of bone loss in these diseases have been much less explored. It has been reported that up to 70% of patients with IBD show some extent of bone loss, and up to 40% present with osteoporosis [75] . Different hypotheses for the bone loss in IBD patients exist. Glucocorticoid treatment, a common therapeutic option for these patients, has been shown to lead to bone loss by different mechanisms. Inflammatory mediators, as well as vitamin D deficiency have been put forward as possible pathological factors in this setting. To our knowledge, this phenomenon has so far not been evaluated in GEMMs for IBD.
Cardiovascular alterations
Artherosclerosis is now considered an inflammatory disease, but the mechanisms leading to the pathogenesis of this condition are poorly understood. In the last decade, several reports have provided evidence for artherosclerosis in psoriasis patients with a higher incidence in patients with PsA, which in certain cases can lead to myocardial infarction or stroke [76] . Many cardiovascular risk factors have been described for patients with psoriasis and PsA, such as cytokines, adipokines, diabetes, obesity, metabolic syndrome (MS), and smoking. Whether these cardiovascular events are related to the metabolic alterations, such as diabetes or obesity, is not clear (see 4.3. below) . Cytokines released from the skin in psoriasis or from joints in PsA enter the circulation and act on distant organs. In the heart, cytokines can activate reactive oxygen species, matrix metalloproteinase, and fibrinogen expression, or increase the adhesiveness of the endothelium [77] [78] [79] .
TNFa produced by different immune cells is a fundamental cytokine in chronic inflammatory diseases. Patients treated with TNFa-blocking agents show lower cardiovascular events and complications, emphasizing the pathogenic role of TNFa in cardiovascular diseases [80] . Interestingly, TNFa inhibition also substantially alters lipids and lipoproteins, indicating that this cytokine links inflammation to metabolic processes. TNFa together with other inflammatory factors stimulates the production of IL-6 in the organ of inflammatory origin, which is important in the pathophysiology of heart diseases. Artherosclerosis risk has been associated with high IL-6 levels, and polymorphisms in IL-6 correlate with increased severity of coronary artery disease as well as infarctions [81] . IL-6 together with TGFb is known to support the differentiation of Th17 cells [82] and IL-6 also activates the JAK/STAT pathway, a critical transcription factor network in many inflammatory and autoimmune diseases [83] .
IL-17 production by Th17 cells and other cell types orchestrates a cascade of downstream signaling augmenting inflammation. Similar to inflammatory skin diseases, artherosclerosis is accompanied by Th17 activation and down-regulation of the activities of regulatory T cells (T-regs). IL-17 levels are up-regulated in patients with coronary artery disease; however, the specific functions of IL-17 in endothelial cells and plaque formation have not been studied in detail [84] . Future studies in GEMMs as well as data from patients treated with IL-17A inhibitors will answer several open questions.
Neutrophils, natural killer, and natural killer T cells are other emerging cell subsets with important roles in cardiovascular alterations in patients with psoriasis and PsA [85, 86] . Recently increased neutrophil number was associated with increased vascular inflammation [87] .
Venous thromboembolic events are associated with IBD. However, whether IBD patients carry a higher risk of cardiovascular diseases is still under debate.
Large-scale studies have been performed to determine the risk of ischemic heart disease and myocardial infarctions in IBD patients with inconsistent results. Although some studies show increased incidence of ischemic heart disease in IBD patients, others show no changes in the risk of developing these comorbidities. Studies assessing cardiovascular mortality in IBD patients also reported contradictory results [88] . These differences could be due to many factors, such as statistical analysis methods, time of analysis (during disease flare or not), as well as environmental elements that vary between hospitals and countries.
Metabolic alterations
As described above, several chronic inflammatory diseases, like psoriasis, AD, and IBD, are characterized by the expression of proinflammatory cytokines such as IL-6, IL-4, TNF-a, and TSLP, which are increased both locally in the skin and systemically in the circulation. It is widely accepted that chronic inflammation can result in metabolic diseases and that the elevated expression of proinflammatory cytokines and of immune mediators can lead to atherogenesis, peripheral insulin resistance, hypertension, and type 2 diabetes [89] . The development of MS is best documented for patients with psoriasis vulgaris, where a threefold increase in metabolic parameters was observed and was more prevalent in women than in men [90] . However, the initial trigger is still under debate. Whether metabolic impairment such as obesity or the preconditioning by a proinflammatory environment, e.g., in psoriasis, predisposes the body to develop the inflammatory disease is still not known.
In AD, a Th2-specific cytokine profile is currently considered central to disease development [91] . A recent meta-analysis derived from AD transcriptome data identifies a robust AD-specific gene signature with a strong involvement of atherosclerosis and altered lipid metabolism pathways [92] . To our knowledge, no convincing reports regarding an increased frequency of MS in AD patients have been published.
Metabolic impairments in patients suffering from IBD are well documented [93] . The extraintestinal manifestations affect nearly all organs and whole body physiology is systemically altered in patients suffering from IBD. Compelling evidence shows that IBD results from an inappropriate inflammatory response to intestinal microbes in genetically susceptible individuals, possibly prone to altered metabolism. The main metabolic and endocrine consequences of IBD include metabolic bone disease, lipid abnormalities, insulin resistance, as well as endocrine functions affecting growth and development. It is argued that the clinical problems are inter-related and that the underlying cause is disease-dependent chronic inflammation, and also the nutritional status. Treatment options such as chronic glucocorticoid therapy may affect some of the systemic alterations, however, little is known about the molecular targets affected by these systemic manifestations.
Conclusions
The pathogenesis of chronic inflammatory diseases has been a topic of investigation for decades. Although a lot of knowledge has been gained from studies involving human samples, GEMMs, and in vitro systems, we still lack a full understanding of the systemic comorbidities of these diseases. Investigations of the molecular mechanisms of communication between organs during homeostasis and in pathological settings are critical for a better design of therapeutic treatments avoiding unwanted secondary effects. Immune cells and inflammatory mediators together with epithelial cells undoubtedly are at center stage controlling the molecular physiology at the organism level in common human diseases (Fig. 1) . We are only now beginning to appreciate and understand the role of the microbiota and antimicrobial proteins in these processes.
As more detailed analyses on the initiation and progression of different inflammatory diseases are available, it will become clear that there are still many open questions. CSI originating from diseases of the same tissue can exert distinct immune responses, as is evident in psoriasis compared to AD. Furthermore, the same cytokines, when originating from different tissues, as in the case of IL-17A in skin vs. intestine, can have completely different roles in homeostasis and distinct effects on disease progression. It will be of great importance to systematically test different inflammatory mediators alone or in combination to determine their contribution to the developing comorbidities. Target molecules of these mediators in different epithelial cells should be identified and characterized. Once carefully dissected, these chemo/cytokines and their target molecules could possibly be used as biomarkers of comorbidities. Another important aspect of immunity is the immune cell itself. More exhaustive analyses of the specific immune cells and their plasticity independent of the molecules they secrete should be performed. We speculate that these cells may move between organs, thereby changing their expression profiles. Certainly GEMMs and PDX models together with the study of patient samples in a thorough manner will prove invaluable to satisfactorily answer the important questions for the benefit of patients.
